AbbVie Inc. (ABBV) Stock Score, Valuation & Financial Research
AbbVie Inc. is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for ABBV
AbbVie Inc. currently has a Wall Street Score of 23/100. The stored market price is $263.01. Its financial score is 22/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What AbbVie Inc. does
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREO
ABBV financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $263.01
- Market capitalization:
- $464.68B
- Revenue:
- $64.39B
- Net income:
- $6.31B
- Free cash flow:
- $17.82B
- Cash:
- $6.57B
- Total debt:
- $70.82B
- EPS:
- 3.55
- P/E ratio:
- 74.1x
- Financial score:
- 22/100
- Valuation score:
- 0/100
- Revenue score:
- 17/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $17.82B, showing positive cash generation.
- The balance sheet shows $6.57B of cash versus $70.82B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ABBV
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.